Rnase l activators and antisense oligonucleotides effective to treat rsv infections
CA 2246503 A1 · Owner: Torrence, Paul F. · Inventors: Silverman, Robert H.; Cirino, Nick M.; Torrence, Paul F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns compounds and methods for treating infection with Respiratory Syncytial Virus. The compounds comprise an antisense portion which is complementary to a normally single stranded portion of the RSV antigenomic strand (the mRNA strand), a linker and an oligonucleotide activator of RNase L, a ubiquitous non-specific RNase. The method comprises forming a complex of an activated RNase L and the antisense molecule. The application teaches methods of determining which portions of the RSV antigenomic strand are normally single-stranded. The application teaches that an antisense oligonucleotide having the sequence of residues 8281-8299 of the RSV genome is particularly …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 14, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 14, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 14, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.